{
  "type": "add_node",
  "timestamp": "2025-08-22T09:24:56",
  "processed": false,
  "inputs": {
    "source_article_id": "COY8LGAVW",
    "status": "rejected",
    "reject_category": "asset",
    "reject_failure_cat": "industry_vertical"
  },
  "details": {
    "llm_topic_proposal_raw": {
      "motivation": "The article highlights the ongoing Phase 2b ASPIRE trial for buloxibutid in idiopathic pulmonary fibrosis (IPF), which is a significant development in the pharmaceutical sector with potential macroeconomic implications for healthcare investments, warranting a new atomic node.",
      "id": "buloxibutid_ipf",
      "name": "Buloxibutid in IPF",
      "type": "asset",
      "level": "driver"
    },
    "topic_category": {
      "category": "asset",
      "motivation": "Specific pharmaceutical drug asset."
    },
    "relevance_gate": {
      "should_add": false,
      "reason": "Buloxibutid is a specific pharmaceutical product in a clinical trial, not a macro driver, tradable asset, policy regime, or geography; it falls under an industry vertical.",
      "confidence": 0.95,
      "failure_category": "industry_vertical"
    }
  },
  "id": "none"
}